Praluent Coverage: Being First May Not Matter As Payers Await Repatha
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.
The pricing advantage that might have been available to Praluent as first-in-class is undercut by the fact that it only has about a month’s lead time over the competition.